EFFICACY OF DOUBLE DOSE VERSUS STANDARD DOSE ERGOCALCIFEROL ON VITAMIN D STATUS AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE

  • Siwimon Areepong Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand
  • Ouppatham Ouppatham Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand
  • Bancha Satirapoj Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand
Keywords: Hyperparathyroidism, Chronic kidney disease, 25-hydroxyvitamin D deficiency, Ergocalciferol

Abstract

Background: Patients with chronic kidney disease (CKD) have an exceptionally high rate of 25-hydroxyvitamin D (25-OHD) deficiency. Modest supplementation with ergocalciferol to raise serum 25-OH-D levels might improve bone and mineral disorders in CKD. Limited evidence is available regarding dosage of ergocalciferol supplement in CKD populations.

Objectives: The study aimed to examine the effectiveness of double-dose ergocalciferol on serum 25-OHD, serum intact parathyroid hormone (PTH) levels and mineral and safety profiles compared with standard-dose ergocalciferol among CKD subjects.

Methods: The study employed a 12-week open labeled, randomized, controlled design among patients with CKD at stages III-IV and serum 25-OHD <30 ng/mL. Patients were randomized in 2 groups: standard dose treated with ergocalciferol as recommended by K/DOQI guidelines or double dose of ergocalciferol from recommendations. Serum testing including 25-OHD, intact PTH, phosphate and calcium was performed at baseline and week 12.

Results: Sixty-three patients were included [standard-dose group (N=30) and double-dose group (N=34)]. At the end of the 12 weeks, 20 (58.8%) patients in the double dose ergocalciferol group achieved sufficiency compared with 6 (20%) patients in the standard dose ergocalciferol group (p<0.05). A significant increase in serum 25-OHD levels (13.6±9.9 vs. 8.5±6.8 ng/mL, p=0.030) and decrease in serum PTH level group (-16.8±26.4 vs. -0.3±26.8 pg/mL, p=0.030) was found in the double-dose group compared with the standard-dose group. No adverse effect was associated with the treatment.

Conclusion: The study demonstrated that high dose oral ergocalciferol had higher efficacy to increase serum 25-OHD and decrease serum PTH levels among patients with CKD than standard-dose ergocalciferol after 12 weeks of treatment.

Downloads

Download data is not yet available.

References

Yadav AK, Kumar V, Kumar V, Banerjee D, Gupta KL, Jha V. The Effect of Vitamin D Supplementation on Bone Metabolic Markers in Chronic Kidney Disease. J Bone Miner Res 2018; 33: 404-9. DOI: https://doi.org/10.1002/jbmr.3314

Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004; 24: 503-10. DOI: https://doi.org/10.1159/000081023

Jayedi A, Soltani S, Shab-Bidar S. Vitamin D status and all-cause mortality in patients with chronic kidney disease: A systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 2017; 102: 2136-45. DOI: https://doi.org/10.1210/jc.2017-00105

Xie S, Huang L, Cao W, et al. Association between serum 25-hydroxyvitamin D and diabetic kidney disease in Chinese patients with type 2 diabetes. PLoS One 2019; 14: e0214728. DOI: https://doi.org/10.1371/journal.pone.0214728

Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011; 58: 374-82. DOI: https://doi.org/10.1053/j.ajkd.2011.03.020

Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75: 88-95. DOI: https://doi.org/10.1038/ki.2008.501

Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-8. DOI: https://doi.org/10.1038/sj.ki.5002009

Alvarez JA, Law J, Coakley KE, et al. Highdose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, doubleblind, placebo-controlled trial. Am J Clin Nutr 2012; 96: 672-9. DOI: https://doi.org/10.3945/ajcn.112.040642

Dogan E, Erkoc R, Sayarlioglu H, Soyoral Y, Dulger H. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Ren Fail 2008;30:407-10. DOI: https://doi.org/10.1080/08860220801964210

Alvarez J, Wasse H, Tangpricha V. Vitamin D supplementation in pre-dialysis chronic kidney disease: A systematic review. Dermatoendocrinol 2012; 4: 118-27. DOI: https://doi.org/10.4161/derm.20014

Thimachai P, Supasyndh O, Chaiprasert A, Satirapoj B. Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25- Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial. J Med Assoc Thai 2015; 98: 643-8.

Alfieri C, Ruzhytska O, Vettoretti S, Caldiroli L, Cozzolino M, Messa P. Native Hypovitaminosis D in CKD Patients: From Experimental Evidence to Clinical Practice. Nutrients 2019; 11: 1918. DOI: https://doi.org/10.3390/nu11081918

Hewison M. Vitamin D and immune function: autocrine, paracrine or endocrine? Scand J Clin Lab Invest Suppl 2012; 243: 92-102.

Goldsmith DJ. Pro: Should we correct vitamin D deficiency/insufficiency in chronic kidney disease patients with inactive forms of vitamin D or just treat them with active vitamin D forms? Nephrol Dial Transplant 2016; 31: 698-705. DOI: https://doi.org/10.1093/ndt/gfw082

Lee YH, Kim JE, Roh YH, et al. The combination of vitamin D deficiency and mild to moderate chronic kidney disease is associated with low bone mineral density and deteriorated femoral microarchitecture: results from the KNHANES 2008-2011. J Clin Endocrinol Metab 2014; 99: 3879-88. DOI: https://doi.org/10.1210/jc.2013-3764

Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007; 27: 36-43. DOI: https://doi.org/10.1159/000098561

Bhan I, Dobens D, Tamez H, et al. Nutritional vitamin D supplementation in dialysis: a randomized trial. Clin J Am Soc Nephrol 2015; 10: 611-9. DOI: https://doi.org/10.2215/CJN.06910714

Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis 2012; 59: 58-66. DOI: https://doi.org/10.1053/j.ajkd.2011.06.027

Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007; 50 :59-68. DOI: https://doi.org/10.1053/j.ajkd.2007.04.010

Oksa A, Spustova V, Krivosikova Z, et al. Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease. Kidney Blood Press Res 2008; 31: 322-9. DOI: https://doi.org/10.1159/000157177

Kandula P, Dobre M, Schold JD, Schreiber MJ, Jr., Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6: 50-62. DOI: https://doi.org/10.2215/CJN.03940510

Arcidiacono MV, Yang J, Fernandez E, Dusso A. The induction of C/EBPbeta contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease. Nephrol Dial Transplant 2015; 30: 423-33. DOI: https://doi.org/10.1093/ndt/gfu311

Satirapoj B, Limwannata P, Chaiprasert A, Supasyndh O, Choovichian P. Vitamin D insufficiency and deficiency with stages of chronic kidney disease in an Asian population. BMC Nephrol 2013; 14: 206. DOI: https://doi.org/10.1186/1471-2369-14-206

Levin GP, Robinson-Cohen C, de Boer IH, et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA 2012; 308: 1898-905. DOI: https://doi.org/10.1001/jama.2012.17304

Published
2020-12-26
How to Cite
1.
Areepong S, Ouppatham O, Satirapoj B. EFFICACY OF DOUBLE DOSE VERSUS STANDARD DOSE ERGOCALCIFEROL ON VITAMIN D STATUS AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE. J Southeast Asian Med Res [Internet]. 2020Dec.26 [cited 2023Mar.23];4(2):59-6. Available from: https://www.jseamed.org/index.php/jseamed/article/view/70
Section
Original Articles

Most read articles by the same author(s)